Archives20242023202220212020201920182017201620152014201320122011 April 12, 2023ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP Read More March 27, 2023Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA Read More March 07, 2023Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy Read More February 06, 2023Phase 2/3 adaptive study design for Lupus study agreed with Avion Read More January 05, 2023Major Interest | TR1 | Gary Smith Read More January 03, 2023Major Interest | TR1 | Lanstead Capital – 3 January 2023 Read More December 22, 2022Grant of Share Options Read More December 22, 2022End of Year Update Read More November 18, 2022Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities Read More September 30, 2022Lupuzor™ Update Read More September 30, 2022INTERIM RESULTS for the six months ended 30 June 2022 Read More September 15, 2022Written response received from the FDA Read More 12345…14
April 12, 2023ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP Read More
March 27, 2023Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA Read More
March 07, 2023Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy Read More
November 18, 2022Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities Read More